Cargando…

Oral eltrombopag versus subcutaneous recombinant human thrombopoietin for promoting platelet engraftment after allogeneic stem cell transplantation: A prospective, non‐inferiority, randomized controlled trial

Delayed platelet engraftment (DPE) is associated with poor survival and increased transplantation‐related mortality after allogeneic hematopoietic stem cell transplantation (allo‐HSCT). Therefore, treatments are needed to improve platelet engraftment and prevent DPE. We performed a phase three, non‐...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wen, Bingbing, Zhang, Xiaohan, Chen, Shiyu, Fan, Jingchao, Yang, Sitian, Cai, Yun, Wang, Pengcheng, Zhang, Qiaoxia, Gu, Qingli, Du, Xin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790607/ https://www.ncbi.nlm.nih.gov/pubmed/35554955 http://dx.doi.org/10.1002/hon.3017

Ejemplares similares

Switching between eltrombopag and recombinant human thrombopoietin in patients with immune thrombocytopenia: an observational study
por: Cai, Xuan, et al.
Publicado: (2022)

Efficacy of Recombinant Human Thrombopoietin for the Treatment of Secondary Failure of Platelet Recovery After Allogeneic HSCT
por: Cao, Yigeng, et al.
Publicado: (2022)

A Real-World Observation of Eltrombopag and Recombinant Human Thrombopoietin (rhTPO) in Lymphoma Patients With Chemotherapy Induced Thrombocytopenia
por: Zhu, Qiuhua, et al.
Publicado: (2021)

Recombinant human thrombopoietin improved platelet engraftment after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma
por: Gu, Jingli, et al.
Publicado: (2021)

Preclinical Activity of Eltrombopag (SB-497115), an Oral, Nonpeptide Thrombopoietin Receptor Agonist
por: Erickson-Miller, Connie L, et al.
Publicado: (2009)

The Thrombopoietin Receptor Agonist Eltrombopag Inhibits Human Cytomegalovirus Replication Via Iron Chelation
por: Vogel, Jens-Uwe, et al.
Publicado: (2019)

PB2425: EFFICACY AND SAFETY OF COMBINED THERAPY OF RECOMBINANT HUMAN THROMBOPOIETIN AND ELTROMBOPAG FOR TREATMENT OF PERSISTENT THROMBOCYTOPENIA AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Pan, Pan, et al.
Publicado: (2023)

The non-peptide thrombopoietin receptor agonist eltrombopag stimulates megakaryopoiesis in bone marrow cells from patients with relapsed multiple myeloma
por: Jeong, Jee-Yeong, et al.
Publicado: (2015)

Recombinant human thrombopoietin promotes platelet recovery in DCAG-treated patients with intermediate-high-risk MDS/hypoproliferative AML
por: Chen, Xiangli, et al.
Publicado: (2023)

The thrombopoietin receptor: revisiting the master regulator of platelet production
por: Hitchcock, Ian S., et al.
Publicado: (2021)

Thrombopoietin participates in platelet activation in COVID-19 patients
por: Lupia, Enrico, et al.
Publicado: (2022)

Platelet storage induces accelerated desialylation of platelets and increases hepatic thrombopoietin production
por: Cho, Jooyoung, et al.
Publicado: (2018)

Recombinant Thrombopoietin Effectively Shortens the Time to Response and Increases Platelet Counts in Elderly Patients with Severe Immune Thrombocytopenia
por: Li, Yang, et al.
Publicado: (2022)

Rescue treatment with eltrombopag in refractory cytopenias after allogeneic stem cell transplantation
por: Aydin, Semra, et al.
Publicado: (2020)

Iron deficiency alters megakaryopoiesis and platelet phenotype independent of thrombopoietin
por: Evstatiev, Rayko, et al.
Publicado: (2014)

Thrombopoietin levels in Quebec platelet disorder—Implications for the mechanism of thrombocytopenia
por: Hayward, C. P. M., et al.
Publicado: (2018)

Recombinant Human Thrombopoietin Accelerates the Recovery of Platelet in Patients With Lower-Risk Myelodysplastic Syndrome: A Proof-of-Concept Study
por: Yang, Yuan, et al.
Publicado: (2021)

Thrombopoietin knock-in augments platelet generation from human embryonic stem cells
por: Zhang, Leisheng, et al.
Publicado: (2018)

Kinetics of neutrophil engraftment in allogeneic stem cell transplantation
por: Kawajiri, Akihisa, et al.
Publicado: (2019)

Eltrombopag for the Treatment of Allogeneic Hematopoietic Stem Cell Transplantation-Related Poor Graft Function
por: Arslan Davulcu, Eren, et al.
Publicado: (2023)

Thrombopoietin and collagen in low doses cooperatively induce human platelet activation
por: Doi, Tomoaki, et al.
Publicado: (2022)

Recombinant human thrombopoietin prior to mobilization chemotherapy facilitates platelet recovery in autologous transplantation in patients with lymphoma: Results of a prospective randomized study
por: Mo, Hongnan, et al.
Publicado: (2021)

Recombinant human thrombopoietin promotes hematopoietic reconstruction after severe whole body irradiation
por: Wang, Chao, et al.
Publicado: (2015)

Use of Eltrombopag in Improving Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation
por: Master, Samip, et al.
Publicado: (2018)

Prophylactic administration of recombinant human thrombopoietin attenuates XELOX or SOX regimen-induced thrombocytopaenia
por: Li, Quanfu, et al.
Publicado: (2021)

Immature platelet fraction and thrombopoietin in patients with liver cirrhosis: A cohort study
por: Rauber, Philip, et al.
Publicado: (2018)

Thrombopoietin Contributes to Enhanced Platelet Activation in Patients with Type 1 Diabetes Mellitus
por: Bosco, Ornella, et al.
Publicado: (2021)

Allogeneic Non-Adherent Bone Marrow Cells Facilitate Hematopoietic Recovery but Do Not Lead to Allogeneic Engraftment
por: Fricke, Stephan, et al.
Publicado: (2009)

Analysis of Allogenicity of Mesenchymal Stem Cells in Engraftment and Wound Healing in Mice
por: Chen, Liwen, et al.
Publicado: (2009)

Mesenchymal Stem Cells Enhance Allogeneic Islet Engraftment in Nonhuman Primates
por: Berman, Dora M., et al.
Publicado: (2010)

Successful treatment of secondary poor graft function post allogeneic hematopoietic stem cell transplantation with eltrombopag
por: Tang, Cen, et al.
Publicado: (2018)

The Clinical Efficacy and Economic Benefits of Recombinant Human Thrombopoietin for the Treatment of Chemotherapy or Chemoradiotherapy-Induced Thrombocytopenia
por: Wang, Wenxian, et al.
Publicado: (2022)

Eltrombopag in Good's Syndrome
por: Kristiansen, Håvard Anton, et al.
Publicado: (2014)

Critical evaluation of the subcutaneous engraftments of hormone naïve primary prostate cancer
por: Valta, Maija, et al.
Publicado: (2020)

High pretransplant hepcidin levels are associated with poor overall survival and delayed platelet engraftment after allogeneic hematopoietic stem cell transplantation
por: Sakamoto, Soichiro, et al.
Publicado: (2016)

The effect of granulocyte colony‐stimulating factor dose and administration interval after allogeneic hematopoietic cell transplantation on early engraftment of neutrophil and platelet
por: Noorazar, Leila, et al.
Publicado: (2021)

Platelet Turnover in Stable Coronary Artery Disease – Influence of Thrombopoietin and Low-Grade Inflammation
por: Larsen, Sanne Bøjet, et al.
Publicado: (2014)

Immature Platelet Counts and Thrombopoietin Plasma Concentrations in Thrombocytopenic and Non-thrombocytopenic Preterm Infants
por: Sallmon, Hannes, et al.
Publicado: (2021)

P1666: EFFECT OF AGONISTS TO THROMBOPOIETIN RECEPTORS ON PLATELET GLYCOME OF PATIENTS WITH IMMUNE THROMBOCYTOPENIA
por: Monzón Manzano, E., et al.
Publicado: (2022)

Durability of platelet response after switching to avatrombopag from eltrombopag or romiplostim in immune thrombocytopenia
por: Al-Samkari, Hanny, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8bmctbtuab3nd1ma6eoeinb0f2